These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 18798735)
1. To make better therapeutics, companies strive to increase the content of results and get them faster. Szpir M Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735 [No Abstract] [Full Text] [Related]
3. Overcoming the obstacles in the pharma/biotech industry: 2008 update. Graul AI; Revel L; Rosa E; Cruces E Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298 [TBL] [Abstract][Full Text] [Related]
5. Discontinued drugs in 2010: oncology drugs. Williams R Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127 [TBL] [Abstract][Full Text] [Related]
6. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development. Perakslis ED; Van Dam J; Szalma S Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001 [No Abstract] [Full Text] [Related]
7. Open innovation: share or die.. Talaga P Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629 [No Abstract] [Full Text] [Related]
8. Traditional drug-discovery model ripe for reform. Cressey D Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796 [No Abstract] [Full Text] [Related]
9. Trends in risks associated with new drug development: success rates for investigational drugs. DiMasi JA; Feldman L; Seckler A; Wilson A Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567 [TBL] [Abstract][Full Text] [Related]
10. Biomedicine. Pharma firms push for sharing of cancer trial data. Bhattacharjee Y Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862 [No Abstract] [Full Text] [Related]
11. 2011 in reflection. Mullard A Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664 [No Abstract] [Full Text] [Related]
12. Novelty in the target landscape of the pharmaceutical industry. Agarwal P; Sanseau P; Cardon LR Nat Rev Drug Discov; 2013 Aug; 12(8):575-6. PubMed ID: 23903214 [No Abstract] [Full Text] [Related]
13. Biotech acquisitions by big pharma: why and what is next. Malik NN Drug Discov Today; 2009 Sep; 14(17-18):818-21. PubMed ID: 19584004 [TBL] [Abstract][Full Text] [Related]
14. Precompetitive research: a new prescription for drug development? Woodcock J Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454 [No Abstract] [Full Text] [Related]
15. Drug discovery in the next decade: innovation needed ASAP. Bennani YL Drug Discov Today; 2011 Sep; 16(17-18):779-92. PubMed ID: 21704185 [TBL] [Abstract][Full Text] [Related]
16. Vas Narasimhan. Narasimhan V; Mullard A Nat Rev Drug Discov; 2016 Jan; 15(1):10-1. PubMed ID: 26718275 [No Abstract] [Full Text] [Related]
17. Q&A: Bernard Munos. Bender E Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392 [No Abstract] [Full Text] [Related]
19. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics. Fitzgerald GA Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453 [TBL] [Abstract][Full Text] [Related]
20. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. Woosley RL; Myers RT; Goodsaid F Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]